Bartlett & Co Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Bartlett & Co Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$595K	Hold	11,100	–	–	0.01%	324
2025 Q4	$582K	Hold	11,100	–	–	0.01%	316
2025 Q3	$719K	Hold	11,100	–	–	0.01%	298
2025 Q2	$540K	Hold	11,100	–	–	0.01%	321
2025 Q1	$378K	Hold	11,100	–	–	0.01%	365
2024 Q4	$437K	Hold	11,100	–	–	0.01%	342
2024 Q3	$521K	Hold	11,100	–	–	0.01%	322
2024 Q2	$600K	Hold	11,100	–	–	0.01%	301
2024 Q1	$757K	Hold	11,100	–	–	0.01%	292
2023 Q4	$714K	Hold	11,100	–	–	0.01%	312
2023 Q3	$504K	Hold	11,100	–	–	0.01%	336
2023 Q2	$623K	Hold	11,100	–	–	0.01%	313
2023 Q1	$502K	Hold	11,100	–	–	0.01%	290
2022 Q4	$451K	Hold	11,100	–	–	0.01%	304
2022 Q3	$725K	Buy	11,100 +6,000	+118%	+$435K	0.02%	239
2022 Q2	$310K	Sell	5,100 -8,500	-63%	-$500K	0.01%	320
2022 Q1	$854K	Hold	13,600	–	–	0.01%	238
2021 Q4	$1.03M	Buy	+13,600	New	+$1.19M	0.02%	230

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bartlett & Co Wealth Management's CRSP Position: Q1 2026 in Review

Bartlett & Co Wealth Management held its CRISPR Therapeutics (CRSP) position steady in Q1 2026 at 11,100 shares worth $595K. The position accounts for 0.01% of the portfolio, ranked #324.

Bartlett & Co Wealth Management first reported a position in CRSP in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.03M in Q4 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Bartlett & Co Wealth Management held 11,100 shares of CRISPR Therapeutics worth $595K as of Q1 2026.
Bartlett & Co Wealth Management left its CRISPR Therapeutics share count unchanged in Q1 2026.
CRISPR Therapeutics made up 0.01% of Bartlett & Co Wealth Management's portfolio in Q1 2026, its #324 holding.
Bartlett & Co Wealth Management first reported a position in CRISPR Therapeutics in Q4 2021 and has held it in 18 quarters since.
Bartlett & Co Wealth Management's CRISPR Therapeutics position peaked at $1.03M in Q4 2021.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Bartlett & Co Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.